Can isolated negative-pressure devices reduce transmission of respiratory infection in critical care units: A laboratory-based controlled experimental observational study

Vollständiger Abstract

Worum geht es in dieser Arbeit?

Background Healthcare workers in critical care settings are at increased risk of acquiring respiratory infections, particularly during aerosol-generating procedures (AGPs). Portable negative-pressure isolation devices have been proposed to fix airborne infection in isolation rooms. Objective To evaluate whether an isolated negative-pressure device reduces bacterial and fungal aerosol dispersion under controlled laboratory conditions. Methods This laboratory-based controlled experimental observational study assessed aerosol containment across three techniques: (1) no cover, (2) plastic sheet canopy barrier, and (3) a portable negative-pressure isolation system. Standardized 5 mL suspensions of Staphylococcus epidermidis and Aspergillus flavus were nebulized on three separate days for each technique. Nutrient agar plates were placed and colony-forming units (CFU) were manually counted. The primary outcome was the mean CFU per technique per day. One-way ANOVA with post-hoc Welch’s t -tests (Bonferroni-corrected) was used for statistical comparison. Results A total of 36 bacterial and fungal plates were analysed. For bacterial aerosols, mean CFU was highest with no cover (535.6 ± 5.38), lower with plastic sheet canopy barrier (429.5 ± 5.41), and lowest with the negative-pressure system (217.5 ± 17.5). Differences were statistically significant (ANOVA p = 9.8 × 10 −8 ; η 2 = 0.995). Fungal CFU demonstrated a similar pattern with significantly lower CFU for Technique 3 compared with both other techniques ( p < .001). Conclusion The negative-pressure isolation device significantly reduced airborne dispersion of bacterial and fungal aerosols compared with plastic sheet canopy barrier methods. These findings support the use of portable negative-pressure systems to enhance aerosol containment during AGPs. Further clinical validation is recommended.